We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

3 hedge funds and large institutions have $177K invested in Progenics Pharmaceuticals Inc in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 126 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% less funds holding

Funds holding: 129 → 3 (-126)

100% less capital invested

Capital invested by funds: $222M → $177K (-$222M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 126

Holders
3
Holders Change
-126
Holders Change %
-97.67%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
126
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$52.6M
2
FCM
Farallon Capital Management
California
-$31.4M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$21.8M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$20.3M
5
State Street
State Street
Massachusetts
-$17.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
– -$301K -79,324 Closed
CS
52
Credit Suisse
Switzerland
– -$297K -78,175 Closed
SOADOR
53
State of Alaska Department of Revenue
Alaska
– -$291K -76,813 Closed
New York State Common Retirement Fund
54
New York State Common Retirement Fund
New York
– -$284K -74,700 Closed
Barclays
55
Barclays
United Kingdom
– -$280K -73,821 Closed
TPSF
56
Texas Permanent School Fund
Texas
– -$280K -73,562 Closed
Thrivent Financial for Lutherans
57
Thrivent Financial for Lutherans
Minnesota
– -$275K -72,429 Closed
VEA
58
Virtus ETF Advisers
New York
– -$273K -71,758 Closed
TD Asset Management
59
TD Asset Management
Ontario, Canada
– -$257K -67,500 Closed
Susquehanna International Group
60
Susquehanna International Group
Pennsylvania
– -$250K -65,909 Closed
Bank of America
61
Bank of America
North Carolina
– -$248K -65,327 Closed
AIG
62
American International Group
New York
– -$227K -59,749 Closed
Wells Fargo
63
Wells Fargo
California
– -$223K -58,882 Closed
AA
64
Ancora Advisors
Ohio
– -$219K -57,700 Closed
Manulife (Manufacturers Life Insurance)
65
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$216K -56,789 Closed
UBS AM
66
UBS AM
Illinois
– -$203K -53,343 Closed
State of Tennessee, Department of Treasury
67
State of Tennessee, Department of Treasury
Tennessee
– -$201K -52,895 Closed
BNP Paribas Financial Markets
68
BNP Paribas Financial Markets
France
– -$199K -52,312 Closed
OC
69
Oppenheimer & Co
New York
– -$190K -50,000 Closed
State Board of Administration of Florida Retirement System
70
State Board of Administration of Florida Retirement System
Florida
– -$171K -45,120 Closed
COPPSERS
71
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$165K -43,483 Closed
VOYA Investment Management
72
VOYA Investment Management
Georgia
– -$165K -43,366 Closed
Citadel Advisors
73
Citadel Advisors
Florida
– -$164K -43,193 Closed
PA
74
Pinnacle Associates
New York
– -$135K -35,630 Closed
OPERF
75
Oregon Public Employees Retirement Fund
Oregon
– -$129K -33,943 Closed
1 2
3
4 5

PGNX Hedge Fund Activity: Q2 2020 in Review

3 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2020, worth a combined $177K — down 100% from $222M a quarter earlier.

Sellers outnumbered buyers: 126 funds closed out of PGNX and 0 opened new positions — a net loss of 126 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $52.6M sold.

  • 3 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2020, down from 129 in Q1 2020.
  • Funds reported $177K of Progenics Pharmaceuticals Inc stock for Q2 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2020 and 126 closed out, a net change of -126 holders.
  • The largest Progenics Pharmaceuticals Inc seller in Q2 2020 was BlackRock, an estimated $52.6M sold.

Based on aggregated 13F filings for Q2 2020.